Thomas Christély

Chief Executive Officer

Chief Executive Officer

Thomas Christély

  • Substantial collaborations and licensing agreements with major international pharma and biotech companies
  • Multiple financing transactions including a reverse IPO at the Alternative Investment Market (AIM) of the London Stock Exchange
  • 2019-2021 Development and sale of the German pharma start-up MYR GmbH to Gilead Sciences Inc. for €1.15 billion plus a milestone payment of a further €300 million

 

Thomas Christély has more than 30 years of experience in general management, finance, corporate & business development at board level – thereof more than 25 years with private and listed biotech and pharmaceutical companies in Europe and the U.S. As CEO of MetrioPharm he focuses on corporate & business development and financing.